[{"id":"1aa44e24-9704-4fe0-a608-34236855cfe0","acronym":"19-C-0017","url":"https://clinicaltrials.gov/study/NCT03745326","created_at":"2021-01-18T18:20:39.102Z","updated_at":"2024-07-02T16:34:38.005Z","phase":"Phase 1/2","brief_title":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients","source_id_and_acronym":"NCT03745326 - 19-C-0017","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" EGFR • PD-L1 • KRAS • ALK • NRAS • HRAS","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12 • HLA-A*11","tags":["EGFR • PD-L1 • KRAS • ALK • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • NRAS mutation • KRAS G12D • EGFR expression • HRAS mutation • KRAS G12 • NRAS G12D • NRAS G12 • HLA-A*11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • anti-KRAS G12D mTCR PBL • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 05/16/2019","start_date":" 05/16/2019","primary_txt":" Primary completion: 12/01/2027","primary_completion_date":" 12/01/2027","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2024-06-05"},{"id":"92f8d52f-8230-4bcf-832a-25726a2e7d8a","acronym":"","url":"https://clinicaltrials.gov/study/NCT03190941","created_at":"2021-01-18T15:44:01.911Z","updated_at":"2024-07-02T16:34:38.067Z","phase":"Phase 1/2","brief_title":"Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients","source_id_and_acronym":"NCT03190941","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" KRAS • ALK • NRAS • HRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V","tags":["KRAS • ALK • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • Proleukin (aldesleukin) • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 09/21/2017","start_date":" 09/21/2017","primary_txt":" Primary completion: 06/29/2027","primary_completion_date":" 06/29/2027","study_txt":" Completion: 06/29/2028","study_completion_date":" 06/29/2028","last_update_posted":"2024-06-05"},{"id":"2b7c4292-573a-4f4f-aeb9-0287544f452d","acronym":"","url":"https://clinicaltrials.gov/study/NCT03592888","created_at":"2021-01-18T17:39:37.238Z","updated_at":"2024-07-02T16:35:05.451Z","phase":"Phase 1","brief_title":"DC Vaccine in Pancreatic Cancer","source_id_and_acronym":"NCT03592888","lead_sponsor":"University of Pennsylvania","biomarkers":" KRAS • HLA-A","pipe":" | ","alterations":" KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12R • HLA-A*03 • KRAS G12 • HLA-A*02 • HLA-A*11","tags":["KRAS • HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12C • KRAS G12D • KRAS G12V • KRAS G12R • HLA-A*03 • KRAS G12 • HLA-A*02 • HLA-A*11"],"overall_status":"Completed","enrollment":" Enrollment 29","initiation":"Initiation: 11/20/2018","start_date":" 11/20/2018","primary_txt":" Primary completion: 02/12/2024","primary_completion_date":" 02/12/2024","study_txt":" Completion: 02/12/2024","study_completion_date":" 02/12/2024","last_update_posted":"2024-05-07"},{"id":"5cfcbe7d-4d03-4117-95be-9b8d7199f4ec","acronym":"","url":"https://clinicaltrials.gov/study/NCT04146298","created_at":"2021-01-18T20:14:11.889Z","updated_at":"2024-07-02T16:35:38.229Z","phase":"Phase 1/2","brief_title":"Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer","source_id_and_acronym":"NCT04146298","lead_sponsor":"Changhai Hospital","biomarkers":" KRAS • NRAS • HRAS","pipe":" | ","alterations":" KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V • KRAS expression","tags":["KRAS • NRAS • HRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • NRAS mutation • KRAS G12V • HRAS mutation • KRAS G12 • NRAS G12 • HLA-A*11 • NRAS G12V • KRAS expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/21/2021","start_date":" 10/21/2021","primary_txt":" Primary completion: 12/01/2024","primary_completion_date":" 12/01/2024","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-09-01"},{"id":"05e2894e-1d38-44e0-96cc-d79414cd4c88","acronym":"V941-001","url":"https://clinicaltrials.gov/study/NCT03948763","created_at":"2021-01-18T19:26:20.412Z","updated_at":"2024-07-02T16:36:04.359Z","phase":"Phase 1","brief_title":"A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)","source_id_and_acronym":"NCT03948763 - V941-001","lead_sponsor":"Merck Sharp \u0026 Dohme LLC","biomarkers":" EGFR • KRAS • ALK • MSI","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • EGFR positive • HLA-A*11","tags":["EGFR • KRAS • ALK • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • EGFR positive • HLA-A*11"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • mRNA-5671"],"overall_status":"Completed","enrollment":" Enrollment 70","initiation":"Initiation: 06/26/2019","start_date":" 06/26/2019","primary_txt":" Primary completion: 08/25/2022","primary_completion_date":" 08/25/2022","study_txt":" Completion: 08/25/2022","study_completion_date":" 08/25/2022","last_update_posted":"2022-09-07"},{"id":"fc0527a0-93cb-423f-bc83-608fc7b18373","acronym":"","url":"https://clinicaltrials.gov/study/NCT05202561","created_at":"2022-01-21T13:53:43.259Z","updated_at":"2024-07-02T16:36:14.829Z","phase":"Phase 1","brief_title":"A Study of RNA Tumor Vaccine in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT05202561","lead_sponsor":"First Affiliated Hospital Bengbu Medical College","biomarkers":" KRAS","pipe":" | ","alterations":" KRAS mutation • KRAS G12D • KRAS G12V • HLA-A*11","tags":["KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • KRAS G12D • KRAS G12V • HLA-A*11"],"overall_status":"Recruiting","enrollment":" Enrollment 10","initiation":"Initiation: 03/10/2022","start_date":" 03/10/2022","primary_txt":" Primary completion: 01/19/2023","primary_completion_date":" 01/19/2023","study_txt":" Completion: 01/19/2024","study_completion_date":" 01/19/2024","last_update_posted":"2022-03-23"},{"id":"5db6a48a-e26f-4cd3-9ad8-969fecb73e0d","acronym":"GLIDE","url":"https://clinicaltrials.gov/study/NCT03091933","created_at":"2022-01-21T22:03:33.454Z","updated_at":"2024-07-02T16:37:15.781Z","phase":"Phase 1/2","brief_title":"Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)","source_id_and_acronym":"NCT03091933 - GLIDE","lead_sponsor":"Ciusss de L'Est de l'Île de Montréal","biomarkers":" HLA-B","pipe":" | ","alterations":" HLA-A*11","tags":["HLA-B"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*11"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 02/06/2017","start_date":" 02/06/2017","primary_txt":" Primary completion: 03/31/2018","primary_completion_date":" 03/31/2018","study_txt":" Completion: 03/31/2019","study_completion_date":" 03/31/2019","last_update_posted":"2017-12-06"},{"id":"f5fd43a8-c358-4b19-914b-50f3d0b72feb","acronym":"","url":"https://clinicaltrials.gov/study/NCT03044743","created_at":"2021-06-23T19:53:49.522Z","updated_at":"2024-07-02T16:37:22.878Z","phase":"Phase 1/2","brief_title":"PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies","source_id_and_acronym":"NCT03044743","lead_sponsor":"Yang Yang","biomarkers":" HLA-A • IFNG","pipe":" | ","alterations":" HLA-A*02 • HLA-A*11 • HLA-A*24","tags":["HLA-A • IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02 • HLA-A*11 • HLA-A*24"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • fludarabine IV • cyclophosphamide intravenous"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 04/07/2017","start_date":" 04/07/2017","primary_txt":" Primary completion: 03/01/2020","primary_completion_date":" 03/01/2020","study_txt":" Completion: 03/01/2022","study_completion_date":" 03/01/2022","last_update_posted":"2017-05-02"}]